Experimental models for predicting drug absorption and metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 10, 2013, Pages 1241-1254

  Alqahtani, Saeed ^a   Mohamed, Loqman A ^a   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Experimental models; Hepatic metabolism; Intestinal absorption; Transporters

Indexed keywords

ALPHA TOCOPHEROL; AMOXICILLIN; ATAZANAVIR; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DAPSONE; GAMMA TOCOTRIENOL; KETOCONAZOLE; LOPERAMIDE; MORPHINE; OMEPRAZOLE; PHENOBARBITAL; PHOSPHODIESTERASE V INHIBITOR; RIFAMPICIN; TACROLIMUS; TERFENADINE; TROGLITAZONE; UK 343664; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE; ZOLPIDEM TARTRATE;

CANCER CELL CULTURE; CELL LINE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSFORMATION; DRUG TRANSPORT; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE PERFUSION; LIVER; LIVER CELL; LIVER CLEARANCE; LIVER TOXICITY; MICROSOME; NONHUMAN; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84884255095     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.802772     Document Type: Review

References (129)

1. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals. J Clin Pharmacol 2002;42:620-43
2. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol 2007;3:469-89
3. Nigsch F, Klaffke W, Miret S. In vitro models for processes involved in intestinal absorption. Expert Opin Drug Metab Toxicol 2007;3:545-56
4. Zolk O, Fromm MF. Transportermediated drug uptake and efflux: Important determinants of adverse drug reactions. Clin Pharmacol Ther 2011;89:798-805
5. US FDA Center for Drug Evaluation and Research. Guidance for industry: Drug interaction studies - Study design, data analysis, implications for dosing, and labeling recommendations. 2012.Available from: Http://www.fda.gov/ downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm292362. pdf [Accessed 24 April 2013]
6. Bohets H, Annaert P, Mannens G, et al. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem 2001;1:367-83
7. Moyer MP. Culture of human gastrointestinal epithelial cells. Proc Soc Exp Biol Med 1983;174:12-5
8. Abuasal BS, Bolger MB, Walker DK, Kaddoumi A. In silico modeling for the nonlinear absorption kinetics of UK-343,664: A P-gp and CYP3A4 substrate. Mol Pharm 2012;9:492-504
9. Gundogdu E, Alvarez IG, Karasulu E. Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: In vitro and in vivo studies. Int J Nanomedicine 2011;6:1631-40
10. Prasad PD, Wang H, Huang W, et al. Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter. Arch Biochem Biophys 1999;366:95-106
11. Terada T, Sawada K, Saito H, et al. Functional characteristics of basolateral peptide transporter in the human intestinal cell line Caco-2. Am J Physiol 1999;276:G1435-41
12. Bleasby K, Chauhan S, Brown CD. Characterization of MPP+ secretion across human intestinal Caco-2 cell monolayers: Role of P-glycoprotein and a novel Na(+)-dependent organic cation transport mechanism. Br J Pharmacol 2000;129:619-25
13. Haikal Z, Play B, Landrier JF, et al. NPC1L1 and SR-BI are involved in intestinal cholesterol absorption from small-size lipid donors. Lipids 2008;43:401-8
14. Sane AT, Sinnett D, Delvin E, et al. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J Lipid Res 2006;47:2112-20
15. Ahlin G, Hilgendorf C, Karlsson J, et al. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab Dispos 2009;37:2275-83
16. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: The role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 2009;6:19-28 . Effect of P-gp in limiting oral absorption of BCS class III drugs
17. Pfrunder A, Gutmann H, Beglinger C, Drewe J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1- MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 2003;55:59-66
18. Balimane PV, Chong S. Cell culture-based models for intestinal permeability: A critique. Drug Discov Today 2005;10:335-43
19. Mekjaruskul C, Yang YT, Leed MG, et al. Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2- hydroxypropyl-beta-cyclodextrin. Int J Pharm 2013;445:1-11
20. Heimbach T, Xia B, Lin TH, He H. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J 2013;15:143-58
21. Subramanian VS, Ghosal A, Subramanya SB, et al. Differentiation-dependent regulation of intestinal vitamin B2 uptake: Studies utilizing human-derived intestinal epithelial Caco2 cells and native rat intestine. Am J Physiol Gastrointest Liver Physiol 2013
22. Sambuy Y, De Angelis I, Ranaldi G, et al. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 2005;21:1-26
23. Briske-Anderson MJ, Finley JW, Newman SM. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 1997;214:248-57
24. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: Methods and studies. Fundam Clin Pharmacol 1999;13:154-68
25. Crespi CL, Penman BW, Hu M. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4. Pharm Res 1996;13:1635-41
26. Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol- 13-acetate. Pharm Res 2001;18:1102-9
27. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 1999;16:625-32
28. Raeissi SD, Guo Z, Dobson GL, et al. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm Res 1997;14:1019-25
29. Braun A, Hammerle S, Suda K, et al. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000;11(Suppl2):S51-60
30. Xia HJ, Zhang ZH, Jin X, et al. A novel drug-phospholipid complex enriched with micelles: Preparation and evaluation in vitro and in vivo. Int J Nanomedicine 2013;8:545-54
31. Hill CR, Jamieson D, Thomas HD, et al. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochem Pharmacol 2013;85:29-37
32. Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 1997;49:627-38
33. Ungell AL, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998;87:360-6
34. van de Kerkhof EG, Ungell AL, Sjoberg AK, et al. Innovative methods to study human intestinal drug metabolism in vitro: Precision-cut slices compared with ussing chamber preparations. Drug Metab Dispos 2006;34:1893-902
35. Clarke LL. A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol 2009;296:G1151-66
36. Haslam IS, O'Reilly DA, Sherlock DJ, et al. Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue. Biopharm Drug Dispos 2011;32:210-21
37. Sjoberg S, Lutz M, Tannergren C, et al. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. Eur J Pharm Sci 2013;48:166-80
38. Polentarutti BI, Peterson AL, Sjoberg AK, et al. Evaluation of viability of excised rat intestinal segments in the Ussing chamber: Investigation of morphology, electrical parameters, and permeability characteristics. Pharm Res 1999;16:446-54
39. Abuznait AH, Cain C, Ingram D, et al. Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: Investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol 2011;63:1111-18
40. Moazed B, Hiebert LM. An in vitro study with an ussing chamber showing that unfractionated heparin crosses rat gastric mucosa. J Pharmacol Exp Ther 2007;322:299-305
41. Berggren S, Lennernas P, Ekelund M, et al. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J Pharm Pharmacol 2003;55:963-72
42. Zakelj S, Sturm K, Kristl A. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 2006;313:175-80
43. Shen Q, Lin Y, Handa T, et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006;313:49-56
44. Shen Q, Li W, Lin Y, et al. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. J Pharm Pharmacol 2008;60:1633-41
45. Rozehnal V, Nakai D, Hoepner U, et al. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur J Pharm Sci 2012;46:367-73
46. Ghai D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective beta(1)- adrenoreceptor blocker talinolol. Nanomedicine 2012;8:618-26
47. Perrone MG, Inglese C, Berardi F, et al. Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor. J Pharmacol Toxicol Methods 2013;67:5-8
48. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 1988;5:651-4
49. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996;13:1336-42
50. Cao F, Gao Y, Wang M, et al. Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: Synthesis, intestinal permeability and pharmacokinetics. Mol Pharm 2013;10(4):1378-87
51. Gupta D, Varghese Gupta S, Dahan A, et al. Increasing oral absorption of polar neuraminidase inhibitors: A prodrug transporter approach applied to oseltamivir analogue. Mol Pharm 2013;10:512-22
52. Mudra DR, Desino KE, Desai PV. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr Drug Metab 2011;12:750-73 . Reviews available models to assess CYP3A and P-gp interplay
53. Kis O, Zastre JA, Hoque MT, et al. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res 2012
54. Kaddoumi A, Fleisher D, Heimbach T, et al. Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: Possible role in dose-dependent pharmacokinetics. J Pharm Sci 2006;95:435-45
55. Abuasal B, Sylvester PW, Kaddoumi A. Intestinal absorption of gamma-tocotrienol is mediated by Niemann-Pick C1-like 1: In situ rat intestinal perfusion studies. Drug Metab Dispos 2010;38:939-45
56. Balimane PV, Chong S, Morrison RA. Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods 2000;44:301-12
57. Antunes F, Andrade F, Ferreira D, et al. Models to predict intestinal absorption of therapeutic peptides and proteins. Curr Drug Metab 2013;14:4-20
58. Lennernas H. Human intestinal permeability. J Pharm Sci 1998;87:403-10
59. Sandstrom R, Knutson TW, Knutson L, et al. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 1999;48:180-9
60. Lennernas H, Knutson L, Knutson T, et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: Experience from a regional perfusion technique. Eur J Pharm Sci 2002;15:271-7
61. Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 2005;24:305-13
62. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11(Suppl2):S73-80
63. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
64. Park BK, Kitteringham NR, Maggs JL, et al. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005;45:177-202
65. Amacher DE. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol 2012;8:335-47
66. Berry MN, Grivell AR, Grivell MB, Phillips JW. Isolated hepatocytes-past, present and future. Cell Biol Toxicol 1997;13:223-33
67. Schaeffner I, Petters J, Aurich H, et al. A microtiterplate-based screening assay to assess diverse effects on cytochrome P450 enzyme activities in primary rat hepatocytes by various compounds. Assay Drug Dev Technol 2005;3:27-38
68. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004;32:1247-53
69. Hewitt NJ, Buhring KU, Dasenbrock J, et al. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 2001;29:1042-50
70. Salonen JS, Nyman L, Boobis AR, et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 2003;31:1093-102
71. Ferrini JB, Pichard L, Domergue J, Maurel P. Long-term primary cultures of adult human hepatocytes. Chem Biol Interact 1997;107:31-45
72. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 2003;4:292-312
73. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Curr Drug Metab 2004;5:443-62
74. Guillouzo A, Morel F, Langouet S, et al. Use of hepatocyte cultures for the study of hepatotoxic compounds. J Hepatol 1997;26(Suppl2):73-80
75. Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discov Today 2004;9:328-36
76. Mitry RR, Hughes RD, Dhawan A. Progress in human hepatocytes: Isolation, culture & cryopreservation. Semin Cell Dev Biol 2002;13:463-7
77. Gomez-Lechon MJ, Castell JV, Donato MT. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chem Biol Interact 2007;168:30-50
78. Runge D, Runge DM, Jager D, et al. Serum-free, long-term cultures of human hepatocytes: Maintenance of cell morphology, transcription factors, and liver-specific functions. Biochem Biophys Res Commun 2000;269:46-53
79. Swift B, Pfeifer ND, Brouwer KL. Sandwich-cultured hepatocytes: An in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 2010;42:446-71
80. Liu X, Chism JP, LeCluyse EL, et al. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 1999;27:637-44
81. Sidler Pfandler MA, Hochli M, Inderbitzin D, et al. Small hepatocytes in culture develop polarized transporter expression and differentiation. J Cell Sci 2004;117:4077-87
82. Camenisch G, Umehara K. Predicting human hepatic clearance from in vitro drug metabolism and transport data: A scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 2012;33:179-94
83. Suzuki H, Sugiyama Y. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. Semin Liver Dis 1998;18:359-76
84. Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005;1:641-54
85. Jeong H, Chiou WL. Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica 2006;36:1-13
86. Yasuda K, Lan LB, Sanglard D, et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002;303:323-32
87. Annaert PP, Brouwer KL. Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2005;33:388-94
88. Marion TL, Leslie EM, Brouwer KL. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 2007;4:911-18
89. Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004;34:243-56
90. Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000;58:361-72
91. Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87
92. Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234
93. Passamonti S, Terdoslavich M, Margon A, et al. Uptake of bilirubin into HepG2 cells assayed by thermal lens spectroscopy. Function of bilitranslocase. FEBS J 2005;272:5522-35
94. Pohl J, Ring A, Stremmel W. Uptake of long-chain fatty acids in HepG2 cells involves caveolae: Analysis of a novel pathway. J Lipid Res 2002;43:1390-9
95. Fosset C, McGaw BA, Reid MD, McArdle HJ. A non-radioactive method for measuring Cu uptake in HepG2 cells. J Inorg Biochem 2005;99:1018-22
96. Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007;168:66-73
97. Nakabayashi H, Taketa K, Miyano K, et al. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982;42:3858-63
98. Antherieu S, Chesne C, Li R, et al. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 2010;38:516-25
99. Sainz B Jr, Chisari FV Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 2006;80:10253-7
100. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 2008;36:1444-52
101. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655-60
102. Lambert CB, Spire C, Claude N, Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 2009;234:345-60
103. Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34:75-83
104. de Kanter R, Monshouwer M, Meijer DK, Groothuis GM. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr Drug Metab 2002;3:39-59
105. Slaus K, Coughtrie MW, Sharp S, et al. Influence of culture system and medium enrichment on sulfotransferase and sulfatase expression in male rat hepatocyte cultures. Biochem Pharmacol 2001;61:1107-17
106. Lake BG, Charzat C, Tredger JM, et al. Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 1996;26:297-306
107. Lake BG, Ball SE, Renwick AB, et al. Induction of CYP3A isoforms in cultured precision-cut human liver slices. Xenobiotica 1997;27:1165-73
108. Martignoni M, Monshouwer M, de Kanter R, et al. Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicol In Vitro 2004;18:121-8
109. Hou T, Wang J, Zhang W, et al. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 2006;13:2653-67
110. Dokoumetzidis A, Kalantzi L, Fotaki N. Predictive models for oral drug absorption: From in silico methods to integrated dynamical models. Expert Opin Drug Metab Toxicol 2007;3:491-505
111. Huang W, Lee SL, Yu LX. Mechanistic approaches to predicting oral drug absorption. AAPS J 2009;11:217-24
112. Kuentz M, Nick S, Parrott N, Rothlisberger D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006;27:91-9
113. Tubic M, Wagner D, Spahn-Langguth H, et al. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006;23:1712-20
114. Parrott N, Lave T. Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 2002;17:51-61
115. Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005;1:159-68
116. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption. Adv Drug Deliv Rev 1996;19:359-76
117. Lehto P, Kortejarvi H, Liimatainen A, et al. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. Eur J Pharm Biopharm 2011;78:531-8
118. Lionberger RA, Raw AS, Kim SH, et al. Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations. Pharm Res 2012;29:1110-20
119. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl1):S41-67
120. Bolger MB, Lukacova V, Woltosz WS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 2009;11:353-63
121. Kovacevic I, Parojcic J, Homsek I, et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2009;6:40-7
122. Monteiro LM, Lione VF, do Carmo FA, et al. Development and characterization of a new oral dapsone nanoemulsion system: Permeability and in silico bioavailability studies. Int J Nanomedicine 2012;7:5175-82
123. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 2010;11:716-29
124. Darwich AS, Pade D, Ammori BJ, et al. A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: Interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol 2012;64:1008-24
125. Jamei M, Turner D, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009;11:225-37
126. Harwood MD, Neuhoff S, Carlson GL, et al. Absolute abundance and function of intestinal drug transporters: A prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm Drug Dispos 2013;34:2-28
127. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
128. Malmborg J, Ploeger BA. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach. J Pharmacol Toxicol Methods 2013;67:203-13
129. Yeo KR, Kenny JR, Rostami-Hodjegan A. Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol 2013; Epub ahead of print